574
Participants
Start Date
May 22, 2023
Primary Completion Date
October 31, 2024
Study Completion Date
December 31, 2024
Local anesthetic injection of CPL-01
Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Naropin, 0.5% Injectable Solution
Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Placebo
Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
RECRUITING
Todd Bertoch, Salt Lake City
Lead Sponsor
Cali Pharmaceuticals LLC
INDUSTRY